Top Page | English | 简体中文 | 繁體中文 | 한국어 | 日本語
Tuesday, 23 January 2024, 08:00 HKT/SGT

Source: Bausch Health Companies Inc
CORRECTION BY SOURCE: Solta Medical's Thermage(R) FLX and TR-4 Return Pad Receive Registration Certifications in China
CORRECTION BY SOURCE: Solta Medical's Thermage(R) FLX and TR-4 Return Pad Receive Registration Certifications in China
(*CORRECTION to the release that was posted earlier on January 18, 2024: The TR-4 Return Pad is approved for use by the U.S. Food & Drug Administration (as part of the Thermage FLX device registration) See sentence below.*)

LAVAL, QC, Jan 23, 2024 - (ACN Newswire) - Bausch Health Companies Inc. (NYSE/TSX:BHC) and Solta Medical, a global leader in the medical aesthetics market, today announced the approval of Thermage® FLX and the TR-4 Return Pad by China's National Medical Products Administration (NMPA). [See *Correction above: The TR-4 Return Pad is not approved for use by the U.S. Food & Drug Administration.]

"The approval of Thermage FLX, and the TR-4 return pad, marks a significant milestone for Solta Medical," Thomas J. Appio, Bausch Health Chief Executive Officer, said. "Not only is this important for growing our business, but it also represents an enormous achievement for our R&D and Regulatory Teams, who worked tirelessly with the NMPA."

Thermage is a non-invasive treatment that uses radiofrequency technology to help tighten and improve the smoothness and texture of the skin's surface to optimize a patient's appearance. Thermage is a versatile and effective treatment that can be used on all skin types and genders, on a wide range of areas on the face, body and around the eyes. Globally, more than two million Thermage treatments have been performed.

"The approval from NMPA means we are able to continue the momentum of the growth of Thermage in China," Jiny Kim, Senior Vice President, Solta Medical, said. "Building on the legacy of Thermage CPT, which has been serving Chinese institutions and consumers effectively since 2015, we look forward to delivering the Thermage FLX proven technology to the Chinese market."


• The radiofrequency energy only delivery components of the Thermage® CPT and FLX system and accessories are indicated for use in:

o Non-invasive treatment of wrinkles around the eyes, including upper and lower eyelids

o Non-invasive treatment of wrinkles

• The simultaneous application of radiofrequency energy and skin vibration by the Thermage® CPT and FLX system and accessories are indicated for use in:

o Non-invasive treatment of wrinkles around the eye

o Non-invasive treatment of wrinkles

o Temporary improvement in the appearance of cellulite

Important Safety Information

Do not undergo Thermage treatment if you have a cardiac pacemaker, a cardioverter, a defibrillator, or any other electrical implant. Let your doctor know if you have an electrical implant or if you have any questions about whether you should undergo a Thermage® treatment.

Solta Medical has not studied the use of the Thermage system:

- Over skin fillers (lips, cheeks, facial wrinkles and skin folds)

- In people who are pregnant and/or breast feeding, diabetic, have an auto-immune disease such as lupus, have cold sores, have genital herpes, or have epilepsy

- In people who have permanent make-up and/or tattoos

- In children

The most commonly reported adverse effect during treatment is mild to moderate pain in the area being treated.

The most commonly reported adverse effects after treatment include the following:

- Mild redness may occur and typically resolves within 24 hours.

- Swelling may occur and typically resolves within 5 days but can remain up to several weeks.

The following adverse effects occur infrequently:

- The procedure may produce heating in the upper layers of the skin, causing burns and subsequent blister and scab formation. There is a possibility of scar formation.

- Skin surface irregularities may appear up to 1 or more months post-treatment.

- Numbness, tingling" or temporary paralysis may occur; typically resolves in a short period of time but may persist up to several weeks.

- Lumps or nodules may occur under the skin primarily in the neck area, and usually resolve within 1 or 2 weeks without chronic or long-term complications.

- Skin may darken, but normally resolves within several months.

Ask your doctor for more information about Thermage FLX and see for additional details.

About Solta Medical

Solta Medical, a business unit of Bausch Health, is a global leader in the medical aesthetics market. Our vision at Solta is to develop and support trusted aesthetic brands that provide value to our customers and their patients. The Thermage® RF systems, Fraxel® laser, Clear + Brilliant® laser, and VASER® ultrasonic system provide exceptional results for patients and lasting growth to physicians due to our foundation of brands that have stood the test of time. More than five million procedures have been performed with Solta Medical's portfolio of products around the world. More information can be found at

About Bausch Health

Bausch Health Companies Inc. (NYSE/TSX:BHC) is a global diversified pharmaceutical company whose mission is to improve people's lives with our health care products. We develop, manufacture and market a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals and eye health, through our controlling ownership interest in Bausch +Lomb. With our leading durable brands, we are delivering on our commitments as we build an innovative company dedicated to advancing global health. For more information, visit and connect with us on Twitter and LinkedIn.

Forward-looking Statements

This news release may contain forward-looking statements about the future performance of Bausch Health, which may generally be identified by the use of the words "anticipates," "hopes," "expects," "intends," "plans," "should," "could," "would," "may," "believes," "subject to" and variations or similar expressions, including statements about the expected results of, and market for, the Company's Thermage® treatment. These statements are based upon the current expectations and beliefs of management and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Actual results are subject to other risks and uncertainties that relate more broadly to Bausch Health's overall business, including those more fully described in Bausch Health's most recent annual report on Form 10-K and detailed from time to time in Bausch Health's other filings with the U.S. Securities and Exchange Commission and the Canadian Securities Administrators, which factors are incorporated herein by reference.

Topic: Press release summary
Source: Bausch Health Companies Inc

Sectors: BioTech, Healthcare & Pharm
From the Asia Corporate News Network

Copyright © 2024 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.

Latest Press Releases
Elevating Possibilities: The Countdown for WBS Dubai Begins!  
Apr 16, 2024 23:33 HKT/SGT
Lexaria Receives Ethics Review Board Approval to Begin New GLP-1 Study  
Apr 16, 2024 21:10 HKT/SGT
InnoEX, Spring Electronics Fair boost tech hub status  
Apr 16, 2024 19:24 HKT/SGT
CleverTap bags ten prestigious awards at the 2024 Stevie Awards   
Apr 16, 2024 19:00 HKT/SGT
Lexus presents Time at the 2024 Milan Design Week  
Tuesday, April 16, 2024 5:49:00 PM
SinoMab BioScience preclinical results of SM17 on atopic dermatitis (AD) published on International Scientific Journal Allergy  
Apr 16, 2024 17:35 HKT/SGT
Autonomix Medical Inc. Covered in Benzinga Article Highlighting Innovative Nerve Treatment Technology  
Apr 16, 2024 17:04 HKT/SGT
Mitsubishi Corporation Announces Participation in a DAC Project in Louisiana, USA  
Tuesday, April 16, 2024 1:36:00 PM
Big CIO Show 2024 Paves the Way for Next-Gen Technological Leadership in AI  
Apr 15, 2024 19:40 HKT/SGT
New circuit challenge for TOYOTA GAZOO Racing  
Monday, April 15, 2024 4:21:00 PM
More Press release >>
More >>
 News Alerts
Copyright © 2024 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Privacy Policy | Terms of Use | RSS
US: +1 214 890 4418 | Beijing: +86 400 879 3881 | Hong Kong: +852 8192 4922 | Singapore: +65 6549 7068 | Tokyo: +81 3 6859 8575

Connect With us: